Xolair Generic Name – Omalizumab

David Fuller

Last Updated On: September 30, 2025

For many people living with severe allergic asthma, treatment with omalizumab has been life-changing. Research shows that patients using this therapy experience fewer asthma flare-ups, better overall control, and improved quality of life compared to standard treatments. Its benefits are not limited to asthma—omalizumab is also used to help manage conditions like chronic spontaneous urticaria and nasal polyps, where traditional therapies often fall short.

Most patients are familiar with the medication by its brand name, Xolair. However, in medical settings and scientific research, its generic name (omalizumab) is just as important. Using the generic name provides consistency across prescriptions, guidelines, and international studies, ensuring clear communication among healthcare professionals worldwide.

In this article, we’ll take a closer look at omalizumab, the generic name for Xolair—exploring how it works, its approved uses, and its significance in today’s treatment landscape.

Key Takeaways

• Omalizumab is the generic name for Xolair, an anti-IgE monoclonal antibody used to treat asthma, chronic hives, nasal polyps, and now food allergies.
• Blocking IgE antibodies interrupts the allergic cascade and reduces inflammation, making it more targeted than steroids or antihistamines.
• In 2025, the FDA approved Omlyclo, the first Xolair biosimilar, expanding access beyond the original brand.
• Healthcare providers often use the generic name in prescriptions, research, and insurance claims, even when dispensing Xolair or Omlyclo.
• Understanding that Xolair and omalizumab are the same drug helps patients navigate treatment and feel confident in their care.

About: Operating since 2016, Med Supply Solutions is known for being one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. If you’re interested in purchasing Xolair online, please contact our sales department for more information.

What Is Omalizumab? Understanding the Biology Behind Xolair

The generic name of Xolair is omalizumab, a biologic therapy that belongs to the class of monoclonal antibodies. Unlike traditional drugs made from chemical compounds, omalizumab is produced using biotechnology. This makes it part of a newer generation of treatments designed to target the immune system more precisely. Patients often ask, “What is Xolair?” The answer is simple: Xolair is the brand name, while omalizumab is the generic name.

Omalizumab binds to immunoglobulin E (IgE), the antibody responsible for triggering allergic reactions. By blocking IgE from attaching to its receptors on immune cells, the drug interrupts the chain of events that cause inflammation, asthma attacks, hives, or food allergy reactions. This targeted action is why omalizumab is sometimes referred to as an anti-IgE antibody therapy, distinguishing it from broader treatments such as steroids or antihistamines.

Clinical Relevance of Omalizumab in Allergy and Immunology

Since its first FDA approval in 2003, omalizumab has changed the way doctors manage several chronic allergic conditions, particularly for patients who don’t respond well to standard therapies. By targeting the IgE pathway, it reduces flare-ups, lessens the need for emergency visits, and improves the quality of life for those living with difficult-to-control conditions.

Key Clinical Uses of Omalizumab

• Moderate-to-Severe Allergic Asthma: Prescribed for patients whose asthma remains uncontrolled with inhaled corticosteroids. Dosing is based on both baseline IgE levels and body weight.
  
• Chronic Spontaneous Urticaria (CSU): Recommended for patients with persistent hives that don’t improve with antihistamines. Omalizumab helps relieve itching and swelling.
  
• Nasal Polyps: For adults whose nasal polyps continue despite surgery or steroid therapy, omalizumab can shrink the growths and improve breathing.
  
• Food Allergies (FDA 2024 approval): Now approved to reduce the risk of reactions, including anaphylaxis, from accidental exposure to common allergens like peanuts, milk, or eggs. It is always used alongside strict avoidance, not as an emergency treatment.

For patients, the distinction between Xolair and omalizumab often comes down to branding and marketing. In reality, they are the same medication; Xolair is the label you see at the pharmacy, while omalizumab is the universal name used in science and medicine.

Regulatory Labeling, Patent Status, and Why No Xolair Generic Exists

For years, patients had no alternative to branded Xolair because it is a biologic, produced with living cells. Unlike chemical drugs, biologics are complex and cannot be copied exactly, which delayed the arrival of generics. Instead, biologics give rise to biosimilars—highly similar versions that match the original in safety and effectiveness.

Until recently, patients relied exclusively on Xolair. But in 2025, the FDA approved Omlyclo (omalizumab-igec), the first Xolair biosimilar. This marked a turning point in access and affordability, offering a new option for patients who previously only had one brand available.

The development of biosimilars took time due to strict regulatory requirements, intellectual property protections, and the scientific complexity of duplicating biologic therapies. With Omlyclo now approved, patients and providers have more flexibility while still receiving the same therapeutic benefits as brand-name Xolair.

Using the Generic Name Omalizumab in Prescriptions and Clinical Documentation

In day-to-day medical practice, clarity is critical. That’s why providers often use the generic name omalizumab in prescriptions, research papers, and insurance claims—even though the brand name Xolair may be more familiar to patients. Both refer to the same medication.

• Prescriptions: Physicians write “omalizumab” to align with international standards.
  
• Clinical Trials: Researchers use the generic name to ensure accuracy when reporting results.
  
• Pharmacy Records: Pharmacists may list omalizumab in formularies and billing systems.
  
• Insurance Claims: Coverage often defaults to the generic name, even if the dispensed product is Xolair or Omlyclo.

For patients, seeing “omalizumab” on paperwork might feel confusing at first. But knowing it is simply another name for Xolair can make treatment feel more transparent and easier to navigate.

Conclusion

Omalizumab is the generic name for Xolair, and together they represent a major step forward in allergy and immunology care. While patients once had access only to brand-name Xolair, the approval of Omlyclo, the first omalizumab biosimilar, marks a new era of expanded access.

Whether referred to by brand or generic name, this anti-IgE monoclonal antibody therapy continues to improve lives by targeting the root cause of allergic inflammation. For patients and providers alike, understanding the dual identity of omalizumab and Xolair helps support informed, confident treatment decisions.

FAQs

1. What is omalizumab?

Omalizumab is a monoclonal antibody that targets immunoglobulin E (IgE), a key antibody involved in allergic reactions. 

2. Is omalizumab the same as Xolair?

Yes. Xolair is the brand name, while omalizumab is the generic name used in prescriptions, research, and clinical documentation. Both terms refer to the same medication.

3. How is omalizumab given?

It is administered as a subcutaneous injection (under the skin), usually every 2 to 4 weeks, depending on body weight and baseline IgE levels. In some cases, patients may self-inject after proper training.

4. How long has omalizumab been available?

Omalizumab was first approved by the FDA in 2003 for asthma. Since then, its use has expanded to multiple allergic and immunologic conditions.

References

Busse WW, Szefler SJ, Haselkorn T, et al. Possible protective effect of omalizumab on lung function decline in patients experiencing asthma exacerbations. The Journal of Allergy and Clinical Immunology in Practice. 2020;9(3):1201-1211. doi:10.1016/j.jaip.2020.10.027

XOLAIR (omalizumab) injection, for subcutaneous use. Prescribing information. Genentech; 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5238lbl.pdf